FrancophonIA/ELRC3.0 huggingface dataset:
English: b Includes subjects who had ≥ 50 copies/mL in the week 48 or week 96 window, subjects who discontinued early due to lack or loss of efficacy, subjects who had a viral load ≥ 50 copies/mL at time of change in background regimen, subjects who discontinued for reasons other than an adverse event (AE), death or lack or loss of efficacy and at the time of discontinuation had a viral load of ≥ 50 copies/mL.
Danish: b Omfatter personer, som havde ≥ 50 kopier/ml i uge 48 vinduet eller uge 96 vinduet, personer, som afbrød behandlingen tidligt som følge af manglende eller svigtende virkning, personer med en virusbelastning på ≥ 50 kopier/ml på tidspunktet for ændring af baggrundsregimet, personer, som afbrød behandlingen af andre årsager end en adverse event (AE), død eller manglende eller svigtende virkning, og som på tidspunktet for seponering havde en virusbelastning på c Omfatter patienter, som afbrød behandlingen som følge af en AE eller død på et tidspunkt fra dag 1 og i løbet af tidsvinduet, hvis dette ikke resulterede i virologiske data om behandlingen i løbet af det specificerede tidsvindue.
English: Animal studies do not indicate harmful effects of elvitegravir on fertility.
Danish: Dyreforsøg indikerer ingen skadelige virkninger af elvitegravir på fertilitet.
English: Relative to fasting conditions, the administration of boosted elvitegravir as the fixed-dose combination 150 mg elvitegravir/150 mg cobicistat/200 mg emtricitabine/245 mg tenofovir disoproxil with a light meal (approximately 373 kcal, 20% fat) or high-fat meal (approximately 800 kcal, 50% fat) resulted in increased exposures of elvitegravir.
Danish: I forhold til fastende tilstand, resulterede administrationen af boosted elvitegravir som fikseret dosis i kombination 150 mg elvitegravir/150 mg cobicistat/200 mg emtricitabin/245 mg tenofovirdisoproxil sammen med et let måltid (ca. 373 kcal, 20 % fedtindhold) eller et måltid med højt fedtindhold (ca. 800 kcal, 50 % fedtindhold) i øgede eksponeringer af elvitegravir.
English: Keep the tablet bottle with you so that you can easily describe what you have taken.
Danish: Tag tabletbeholderen med, så De let
English: Boosting elvitegravir with an agent other than ritonavir may result in suboptimal plasma concentrations of elvitegravir and/or the protease inhibitor leading to loss of therapeutic effect and possible development
Danish: Boosting af elvitegravir med et andet middel end ritonavir kan resultere i suboptimale plasmakoncentrationer af elvitegravir og/eller af proteasehæmmeren, der medfører svigtende terapeutisk virkning og mulig udvikling af resistens.
English: Co-administration of Vitekta with strong CYP3A inducers (including St. John's wort [Hypericum perforatum], rifampicin, carbamazepine, phenobarbital and phenytoin) is contraindicated (see sections 4.3 and 4.5).
Danish: Samtidig administration af Vitekta med stærke CYP3A-inducere (inklusive prikbladet perikum [Hypericum perforatum], rifampicin, carbamazepin, phenobarbital og phenytoin) er kontraindiceret (se pkt.
English: The use of Vitekta with HIV-1 protease inhibitors or dosing frequencies other than those presented in Table 1 may result in inadequate or elevated plasma levels of elvitegravir and/or the co-administered medicinal products.
Danish: Anvendelse af Vitekta med andre hiv-1-proteasehæmmere eller doseringsfrekenser end dem, der er anført i tabel 1, kan resultere i utilstrækkelige eller forhøjede plasmaniveauer af elvitegravir og/eller de samtidigt administrerede lægemidler.
English: 1.6% (-33.0% to 36.2%)
Danish: 1,6 % (-33,0 % til 36,2 %)
English: High density polyethylene (HDPE) bottle with a child-resistant closure containing 30 film-coated
Danish: Højdensitets-polyethylen (HDPE)- tabletbeholder med børnesikret lukke indeholdende
English: If the patient misses a dose of Vitekta within 18 hours of the time it is usually taken, the patient should take Vitekta with food as soon as possible and resume the normal dosing schedule.
Danish: Hvis patienten glemmer at tage en dosis Vitekta i mindre end 18 timer efter tidspunktet, hvor patienten normalt tager dosen, skal patienten tage Vitekta sammen med mad så snart som muligt og derefter fortsætte med den normale doseringsplan.
English: Elvitegravir is a modest inducer and may have the potential to induce CYP2C9 and/or inducible UGT enzymes.
Danish: Elvitegravir er en moderat inducer og kan potentielt inducere CYP2C9 og/eller inducerbare UGTenzymer.
English: A study of the pharmacokinetics of boosted elvitegravir was performed in non HIV-1 infected subjects with severe renal impairment (estimated creatinine clearance below 30 mL/min).
Danish: Et farmakokinetikstudie af boosted elvitegravir blev udført hos non-hiv-1-inficerede personer med svært nedsat nyrefunktion (estimeret kreatininclearance under 30 ml/min).
English: Recommendation concerning co-administration with ritonavir-boosted elvitegravir
Danish: samtidig administration af ritonavirboosted elvitegravir
English: The in vitro antiviral activity of elvitegravir when combined with antiretroviral drugs from the nucleos(t)ide reverse transcriptase inhibitor (NRTI), non-nucleoside reverse transcriptase inhibitor (NNRTI), protease inhibitor (PI), integrase strand transfer inhibitor, fusion inhibitor, or CCR5 co-receptor antagonist classes showed no
Danish: Elvitegravirs antivirale aktivitet in vitro i kombination med antiretrovirale lægemidler fra den nukleos(t)ide reverse transkriptasehæmmer (NRTI), non-nukleoside reverse transkriptasehæmmer (NNRTI), proteasehæmmer (PI), integrase strand transfer-hæmmer, fusionshæmmer eller CCR5 co-receptor antagonistklasser udviste ingen
English: Excipient with known effect: Each tablet contains 10.9 mg lactose (as monohydrate).
Danish: Hjælpestof, som behandleren skal være opmærksom på: Hver tablet indeholder 10,9 mg lactose (som
English: For example, atazanavir/ritonavir and lopinavir/ritonavir (potent UGT1A1/3 inhibitors) have been shown to significantly increase the plasma concentrations of elvitegravir (see Table 2).
Danish: For eksempel er det påvist, at atazanavir/ritonavir og lopinavir/ritonavir (kraftige hæmmere af UGT1A1/3) forhøjer plasmakoncentrationerne af elvitegravir signifikant (se tabel 2).
English: Assessment of adverse reactions is based on data from a controlled clinical study (GS-US-183-0145) in which 712 HIV-1 infected, antiretroviral treatment-experienced adults received elvitegravir (n = 354) or raltegravir (n = 358) each administered with a background regimen consisting of a fully active ritonavir-boosted protease inhibitor and other antiretroviral agents.
Danish: Vurdering af bivirkninger er baseret på data fra et kontrolleret klinisk studie (GS-US-183-0145), hvori 712 hiv-1-inficerede, tidligere antiretrovirale behandlede voksne modtog elvitegravir (n= 354) eller raltegravir (n= 358), som hver blev administreret med et baggrundsregime, der bestod af en fuldt effektiv ritonavir-boosted proteasehæmmer og andre antiretrovirale midler.
English: Co-administration of elvitegravir with oral contraceptives containing progestagens other than norgestimate have not been studied and, therefore, should be avoided.
Danish: Samtidig administration af elvitagravir og orale antikonceptiva, der indeholder andre progestagener end norgestimat er ikke undersøgt og bør derfor undgås.
English: Phenotypic resistance to elvitegravir was most commonly associated with the primary integrase substitutions T66I, E92Q and Q148R.
Danish: Fænotyperesistens over for elvitegravir var hyppigst forbundet med de primære integrasesubstitutioner T66I, E92Q og
English: C]elvitegravir, 94.8% of the dose was recovered in faeces, consistent with the hepatobiliary elimination of elvitegravir; 6.7% of the administered dose was recovered in urine as metabolites.
Danish: C]elvitegravir blev 94,8 % af dosis genfundet i fæces i overensstemmelse med den hepatobiliære elimination af elvitegravir.
English: If you notice any of these symptoms, tell your doctor.
Danish: Hvis De bemærker nogle af disse symptomer, skal De fortælle det til lægen.
English: Interaction not studied with elvitegravir.
Danish: Interaktion er ikke undersøgt med elvitegravir.
English: Pack size: 1 bottle of 30 film-coated tablets.
Danish: Pakningsstørrelse: 1 tabletbeholder med 30 filmovertrukne tabletter.
English: Discontinued study drug due to AE or death c
Danish: Seponerede studiemedicin som følge af AE (adverse event)
English: Virologic failure No virologic data at week 48 or week 96 window
Danish: Ingen virologiske data ved uge 48- eller uge 96-vinduet
English: Co-administration of Vitekta with medicinal products that are potent inhibitors of UGT1A1/3 may result in increased elvitegravir plasma concentrations and dose modifications may be required.
Danish: Samtidig administration af Vitekta med lægemidler, der er kraftige hæmmere af UGT1A1/3, kan resultere i forhøjede plasmakoncentrationer af elvitegravir, og dosisjusteringer kan være nødvendige.
English: In study GS-US-183-0145, the mean increase from baseline in CD4+ cell count at week 96 was in the elvitegravir-treated patients and 198 cells/mm in the raltegravir-treated patients.
Danish: I studie GS-US-183-0145 var den gennemsnitlige stigning i CD4+ celletal fra baseline ved uge 96 hos patienter behandlet med elvitegravir, og 198 celler/mm hos patienter behandlet
English: Plasma concentrations of elvitegravir are not expected to change upon co-administration of OATP substrates/inhibitors.
Danish: Plasmakoncentrationer af elvitegravir forventes ikke at ændres ved samtidig administration af OATPsubstrater/hæmmere.
English: In these combinations the dose is one 85 mg tablet each day, with food.
Danish: I disse kombinationer er dosis én 85 mg tablet hver dag sammen med mad.
English: Co-administration of Vitekta with medicinal products that are moderate inducers of CYP3A (including, but not limited to, efavirenz and bosentan) is not recommended as the expected decrease in plasma concentrations of elvitegravir can lead to loss of therapeutic effect and possible development of resistance to elvitegravir (see section 4.4).
Danish: Samtidig administration af Vitekta med lægemidler, der er moderate inducere af CYP3A (inklusive, men ikke begrænset til efavirenz og bosentan) anbefales ikke, da det forventede fald i plasmakoncentrationer af elvitegravir kan forårsage svigtende terapeutisk virkning og mulig udvikling af resistens over for elvitegravir (se pkt.
English: In study GS-US-183-0145, patients were randomised in a 1:1 ratio to receive either elvitegravir (150 mg or 85 mg) once daily or raltegravir 400 mg twice daily, each administered with a background regimen (BR) containing a fully-active ritonavir-boosted protease inhibitor (either atazanavir, darunavir, fosamprenavir, lopinavir or tipranavir) and a second agent.
Danish: I studie GS-US-183-0145 blev patienterne randomiseret 1:1 til at få enten elvitegravir (150 mg eller 85 mg) én gang dagligt eller raltegravir 400 mg to gange dagligt, hver administreret med et baggrundsregime (BR), der indeholdt en fuldt effektiv ritonavir-boosted proteasehæmmer (enten atazanavir, darunavir, fosamprenavir, lopinavir eller tipranavir) og et andet middel.
English: • St. John's wort (Hypericum perforatum), a herbal remedy used for depression and anxiety, or products that contain it
Danish: • prikbladet perikum (Hypericum perforatum), et naturlægemiddel, der anvendes til depression og angst) eller lægemidler, der indeholder det
English: a Week 48 window is between day 309 and 364 (inclusive), week 96 window is between day 645 and 700 (inclusive).
Danish: Uge 96 vindue er fra dag 645 til 700 (inklusive).
English: 126/202 (62.4%) 122/207 (58.9%) 3.4% (-6.0% to 12.9%) 2.9% (-13.7% to 19.6%)
Danish: 126/202 (62,4 %) 122/207 (58,9 %) 3,4 % (-6,0 % til 12,9 %) 2,9 % (-13,7 % til 19,6 %)
English: Excipient with known effect: Each tablet contains 6.2 mg lactose (as monohydrate).
Danish: Hjælpestof, som behandleren skal være opmærksom på: Hver tablet indeholder 6,2 mg lactose (som
English: The efficacy of elvitegravir is primarily based on the analyses through 96 weeks from one randomised, double-blind, active-controlled study, study GS-US-183-0145, in treatment-experienced,
Danish: Virkningen af elvitegravir er primært baseret på analyser til og med 96 uger fra et randomiseret, dobbeltblindet, aktivt kontrolleret studie, studie GS-US-183-0145, hos behandlingserfarne
English: Women of childbearing potential / contraception in males and females The use of Vitekta must be accompanied by the use of effective contraception (see sections 4.4
Danish: Kvinder i den fertile alder / kontraception til mænd og kvinder Anvendelsen af Vitekta skal ledsages af sikker kontraception (se pkt.
English: Therefore, Vitekta should not be used during breastfeeding.
Danish: Vitekta må derfor ikke anvendes under amning.
English: In these combinations the dose is one 150 mg tablet each day, with food.
Danish: I disse kombinationer er dosis én 150 mg tablet hver dag sammen med mad.
English: 7.1% (-47.1% to 61.4%)
Danish: 7,1 % (-47,1 % til 61,4 %)
English: In an in vitro chromosomal aberration test, elvitegravir was negative with metabolic activation; however, an equivocal response was observed
Danish: I en in vitro kromosomal aberrationstest var elvitegravir negativ med metabolisk aktivering.
English: -0.5% (95% CI = -7.9%, 6.8%)
Danish: 2,2 % (95 % CI = -5,0 %, 9,3 %) -0,5 % (95% CI = -7,9%, 6,8%)
English: Weight and levels of blood lipids and glucose may increase during antiretroviral therapy (see
Danish: Kropsvægt og niveauerne af lipid og glucose i blodet kan stige under antiretroviral behandling (se
English: ↑ Ketoconazole§
Danish: Ελλάδα
English: C. OTHER CONDITIONS AND REQUIREMENTS OF THE
Danish: C. ANDRE FORHOLD OG BETINGELSER FOR MARKEDSFØRINGSTILLADELSEN
English: Take the 150 mg tablet at the same time as the first dose of darunavir or fosamprenavir and ritonavir.
Danish: Tag 150 mg tabletten samtidigt med den første dosis af darunavir eller fosamprenavir og ritonavir.
English: However, the maximum exposures evaluated in the rabbit were not in excess of those achieved therapeutically (see section 5.3).
Danish: Dog, var de maksimale dosis eksponeringer, der blev undersøgt hos kaniner, ikke højere end de vanligt terapeutiske dosis eksponeringer (se pkt.
English: There are no or limited clinical data with elvitegravir in pregnant women.
Danish: Der er ingen eller utilstrækkelige kliniske data fra anvendelse af elvitegravir til gravide kvinder.
English: suicidal ideation and suicide attempt (in patients with a pre-existing history of depression or psychiatric illness), depression, insomnia dizziness, paraesthesia, somnolence, dysgeusia abdominal pain, diarrhoea, vomiting, nausea dyspepsia, abdominal distension, flatulence
Danish: Tabel 3: Resumé af bivirkninger forbundet med elvitegravir baseret på erfaringer efter 96 uger selvmordstanker og selvmordsforsøg (hos patienter med en eksisterende anamnese med depression eller en psykisk sygdom), depression, søvnløshed svimmelhed, paræstesi, døsighed, dysgeusi abdominalsmerter, diarré, opkastning, kvalme dyspepsi, abdominal distension, flatulens
English: Caution should be exercised when co-administering Vitekta and a hormonal contraceptive.
Danish: Der bør udvises forsigtighed, når Vitekta og hormonale antikonceptiva administreres samtidigt.
English: What you need to know before you take Vitekta Do not take Vitekta
Danish: Det skal De vide, før De begynder at tage Vitekta Tag ikke Vitekta
English: Skin and subcutaneous tissue disorders: General disorders and administration site conditions:
Danish: Almene symptomer og reaktioner på administrationsstedet:
English: Take the 150 mg tablet at the same time as the first dose of darunavir or fosamprenavir
Danish: Tag 150 mg tabletten samtidigt med den første dosis af darunavir eller
English: The hormonal contraceptive should contain at least 30 µg ethinylestradiol and contain norgestimate as the progestagen or patients should use an alternative reliable method of contraception (see sections 4.4 and 4.6).
Danish: De hormonale antikonceptiva bør indeholde mindst 30 µg ethinylestradiol og indeholde norgestimat som progestagenet, eller patienterne skal anvende en anden sikker kontraceptionsmetode (se pkt.
English: 150 mg once daily darunavir 600 mg and ritonavir 100 mg twice daily fosamprenavir 700 mg and ritonavir 100 mg twice daily
Danish: 150 mg én gang dagligt darunavir 600 mg og ritonavir 100 mg to gange dagligt fosamprenavir 700 mg og ritonavir 100 mg to gange dagligt
English: Virologic success rates at week 96 for elvitegravir and raltegravir were 39.0% (23/59) and 52.2% (35/67) (difference: -8.4% [95% CI: -26.1% to 9.2%]), respectively, for female subjects, and 55.1% (161/292) and 53.2% (151/284) (difference: 1.5% [95% CI: -6.5% to 9.6%]), respectively, for male subjects.
Danish: Virologisk succesrate ved uge 96 for elvitegravir og raltegravir var hhv. 39,0 % (23/59) og 52,2 % (35/67) (forskel: -8,4 % [95 % CI: -26,1 % til 9,2 %]) for kvinder og hhv. 55,1 % (161/292) og 53,2 % (151/284) (forskel: 1,5 % [95 % CI: -6,5 % til 9,6 %]) for mænd.
English: 85 mg once daily atazanavir 300 mg and ritonavir 100 mg once daily lopinavir 400 mg and ritonavir 100 mg twice daily
Danish: 85 mg én gang dagligt atazanavir 300 mg og ritonavir 100 mg én gang dagligt lopinavir 400 mg og ritonavir 100 mg to gange dagligt
English: In study GS-US-183-0145, subgroup analyses by co-administered protease inhibitor showed similar rates of virologic success for elvitegravir and raltegravir within each protease inhibitor subgroup at weeks 48 and 96 (HIV-1 RNA < 50 copies/mL) (Table 6).
Danish: I studie GS-US-183-0145 påviste subgruppeanalyse af samtidigt administreret proteasehæmmer sammenlignelige rater for virologisk success for elvitegravir og raltegravir inden for hver proteasehæmmer-subgruppe ved uge 48 og uge 96 (hiv-1-rna < 50 kopier/ml) (tabel 6).
English: A study of the pharmacokinetics of boosted elvitegravir was performed in non-HIV-1 infected subjects with moderate hepatic impairment (Child-Pugh Class B).
Danish: Et farmakokinetikstudie af boosted elvitegravir blev udført hos non-hiv-1-inficerede personer med moderat nedsat leverfunktion (Child-Pugh klasse B).
English: Elvitegravir-resistant viruses show cross-resistance to the integrase strand transfer inhibitor raltegravir
Danish: Elvitegravir-resistente vira viser i de fleste tilfælde krydsresistens over for integrase strand transfer
English: Female patients of childbearing potential should use either a hormonal contraceptive containing at least 30 µg ethinylestradiol and containing norgestimate as the progestagen or should use an alternative reliable method of contraception (see sections 4.5 and 4.6).
Danish: Kvindelige patienter i den fertile alder skal enten anvende hormonale antikonceptiva, der indeholder mindst 30 µg ethinylestradiol samt norgestimat som progestagen eller anvende anden sikker kontraceptionsmetode (se pkt.
English: No data are available on which to make a dose recommendation for patients over the age of 65 years
Danish: Der foreligger ingen data, hvorpå der kan laves en dosisanbefaling til patienter over 65 år (se pkt.
English: Raltegravir + background regimen n = 351
Danish: Raltegravir + baggrundsregime n = 351
English: Consequently, patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption should not take this medicinal product.
Danish: Bør ikke anvendes til patienter med arvelig galactoseintolerans, en særlig form af hereditær lactasemangel (Lapp Lactase Deficiency) eller glucose/galactosemalabsorption.
English: Patients with HIV and hepatitis B or C virus co-infection Patients with chronic hepatitis B or C treated with antiretroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse reactions.
Danish: Patienter med hiv, som samtidig er inficerede med hepatitis B- eller C-virus Hos patienter med kronisk hepatitis B eller C, som er i antiretroviral behandling, er der en øget risiko for svære og potentielt letale, hepatiske bivirkninger.
English: Vitekta should not be used in combination with products containing elvitegravir or pharmacokinetic
Danish: Vitekta bør ikke anvendes i kombination med andre produkter, der indeholder elvitegravir eller andre farmakokinetiske forstærkende midler end ritonavir.
English: 9.0% (-9.5% to 27.5%) -11.1% (-45.7% to 23.4%)
Danish: 9,0 % (-9,5 % til 27,5 %) -11,1 % (-45,7 % til
English: When used in combination with Vitekta, the recommended dose of atazanavir is 300 mg with ritonavir 100 mg once daily.
Danish: Ved brug i kombination med Vitekta er den anbefalede dosis atazanavir 300 mg med ritonavir 100 mg én gang dagligt.
English: In an analysis of HIV-1 isolates from treatment-failure subjects in study GS-US-183-0145 through week 96, the development of one or more primary elvitegravir resistance-associated substitutions was observed in 23 of the 86 subjects with evaluable genotypic data from paired baseline and elvitegravir treatment-failure isolates (23/351 elvitegravir-treated subjects, 6.6%).
Danish: I en analyse af hiv-1-isolater fra personer med behandlingssvigt i studie GS-US-183-0145 til og med uge 96 blev udviklingen af en eller flere primære elvitegravir-resistensassocierede substitutioner observeret hos 23 ud af 86 personer med evaluerbare genotypedata fra parrede baseline- og elvitegravir behandlingssvigtisolater (23/351 elvitegravir-behandlede personer, 6,6 %).
English: The steady-state mean Cmax, AUCtau, and Ctrough (mean ± SD) following multiple doses of elvitegravir plus a ritonavir-boosted protease inhibitor (150 mg elvitegravir with darunavir or fosamprenavir; 85 mg elvitegravir with atazanavir or lopinavir) in HIV-1 infected subjects were 1.4 ± 0.39 μg/mL, 18 ± 6.8 μg•h/mL, and 0.38 ± 0.22 μg/mL for elvitegravir, respectively.
Danish: Steadystate gennemsnitlige værdier for Cmax, AUCtau og Ctrough (gennemsnit ± SD) efter flere doser af elvitegravir plus en ritonavir-boosted proteasehæmmer (150 mg elvitegravir med darunavir eller fosamprenavir, 85 mg elvitegravir med atazanavir eller lopinavir) hos hiv-1-inficerede personer var hhv. 1,4 ± 0,39 μg/ml, 18 ± 6,8 μg•t/ml og 0,38 ± 0,22 μg/ml for elvitegravir.
English: Elvitegravir + background regimen n = 351
Danish: Elvitegravir + baggrundsregime n = 351
English: • herbal products: St. John's wort (Hypericum perforatum)
Danish: • naturlægemidler: prikbladet perikum (Hypericum perforatum)
English: Table 5: Virologic outcome of randomised treatment of study GS-US-183-0145 at week 48 and
Danish: Tabel 5: Virologisk resultat af randomiseret behandling for studie GS-US-183-0145 ved uge 48
English: No dose adjustment of Vitekta is required when co-administered with reduced dose of rifabutin.
Danish: Dosisjustering af Vitekta er ikke nødvendig ved samtidig administration med en reduceret dosis af rifabutin.
English: 105/202 (52.0%) 112/207 (54.1%) -2.1% (-11.8% to 7.5%) -1.5% (-18.2% to 15.3%)
Danish: 105/202 (52,0 %) 112/207 (54,1 %) -2,1 % (-11,8 % til 7,5 %) -1,5 % (-18,2 % til 15,3 %)
English: The antiviral activity of elvitegravir against laboratory and clinical isolates of HIV-1 was assessed in lymphoblastoid cells, monocyte/macrophage cells, and peripheral blood lymphocytes and the 50% effective concentration (EC50) values were in the range of 0.02 to 1.7 nM. Elvitegravir displayed antiviral activity in cell culture against HIV-1 clades A, B, C, D, E, F, G, and O (EC50 values ranged from 0.1 to 1.3 nM) and activity against HIV-2 (EC50 of 0.53 nM).
Danish: 50 % effektiv koncentrationsværdier (EC50) forelå i intervallet fra 0,02 til 1,7 nM. Elvitegravir udviste antiviral aktivitet i cellekultur mod hiv-1-kladerne A, B, C, D, E, F, G og O (EC50-værdier var i intervallet fra 0,1 til 1,3 nM) og aktivitet mod hiv-2 (EC50 af 0,53 nM).
English: Signs of osteonecrosis are: - joint stiffness - joint aches and pains (especially of the hip, knee and shoulder) - difficulty with movement.
Danish: smerter i led (især i hofter, knæ og skuldre)